Exelixis | EXEL - Pasivo Circulante





Pasivo Circulante Cambio Fecha
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
Akebia Therapeutics USD 173.88M 10.95M 2026-03
Amgen USD 24.96B 534M 2026-03
AstraZeneca USD 31.55B 1.02B 2026-06
Bayer EUR 33.46B 875M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Cytokinetics USD 199.18M 3.27M 2026-03
Eisai JPY 340.25B 47.42B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Exelixis USD 370.98M 34.67M 2026-03
Genmab DKK 1.43B 686M 2025-12
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Incyte USD 1.31B 177.55M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
MacroGenics USD 95.94M 52.82M 2026-03
Merck USD 26.94B 1.38B 2026-03
Moderna USD 2.53B 139M 2026-06
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06
Pfizer USD 34.35B 2.64B 2026-03
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sanofi EUR 30.01B 1.66B 2026-03
Takeda JPY 2.76T 335.02B 2026-06
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Xencor USD 73.46M 22.45M 2026-03